Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 6/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.42 |
| ▸ | EEF2K | O00418 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15728295 | 0.94 | TRPA1 (0.54) | TRPA1NAMPTNOTUMSUV39H2CKS1B | |
| SCHEMBL803637 | 0.87 | IRAK1 (0.49) | TRPA1NAMPTIRAK1PRMT5DRD2 | |
| SCHEMBL10232262 | 0.87 | NAMPT (0.55) | NAMPTIRAK1PRMT5DRD2NPC1L1 | |
| SCHEMBL948774 | 0.87 | CKS1B (0.52) | TRPA1NAMPTNOTUMDRD2DRD4 | |
| SCHEMBL13346444 | 0.84 | TRPA1 (0.58) | TRPA1NOTUMDRD2DRD4 | |
| SCHEMBL25153742 | 0.82 | MAPT (0.59) | NAMPTNPC1L1 | |
| SCHEMBL22499945 | 0.81 | MAP4K4 (0.51) | NOTUM | |
| SCHEMBL25080907 | 0.81 | NOTUM (0.54) | NAMPTNOTUMDRD2SUV39H2CKS1B | |
| SCHEMBL21664344 | 0.80 | CCRL2 (0.57) | NAMPTIRAK1PRMT5CCRL2 | |
| SCHEMBL30112888 | 0.80 | CCRL2 (0.57) | NAMPTIRAK1PRMT5CCRL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359337-B2 | Acetamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359337-B2 | Acetamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359337-B2 | Acetamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150246906-A1 | NOVEL ACETAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246906-A1 | NOVEL ACETAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246906-A1 | NOVEL ACETAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2379525-B1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INT (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| EP-2816040-A1 | Process for the production of CCR2 receptor antagonists and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | EP | disclosed |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8835440-B2 | Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| WO-2014076038-A1 | NOVEL ACETAMIDE DERIVATIVES AS TRP CHANNEL ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-22 | — | — | WO | disclosed |
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | CCR2, CCR1, CCR5 | TRPA1 221/4885NAMPT 597/4885IRAK1 186/4885 |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | CCR2, CCR5, CCR1 | TRPA1 380/4885NAMPT 633/4885IRAK1 251/4885 |
| US-20150246906-A1 | NOVEL ACETAMIDE DERIVATIVES | ADCY4, ADCY3, ADCY1 | TRPA1 779/4885NAMPT 1231/4885IRAK1 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.